Heart failure & diabetes: SGLT2 inhibition, a paradigm shift?
Topic:
Diabetes management
Speaker:
Professor J. McMurray (Glasgow, GB)
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly
Event:
ESC Congress 2016
Congress Presentation
About the speaker
Professor John J V McMurray
University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
125
presentations
16
followers
4 more presentations in this session
Introduction - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?
Speaker: Doctor D. Fitchett (Toronto, CA)
Challenging CV Risk in diabetes: ready for a new approach?
Speaker: Professor J. Deanfield (London, GB)
SGLT-2 inhibitors in T2DM management: current position & future promise.
Speaker: Professor S. Inzucchi (New Haven, US)
Panel discussion - SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?
Speaker: Doctor D. Fitchett (Toronto, CA) Professor J. McMurray (Glasgow, GB)
Access the full session
SGLT2 inhibition, diabetes and CVD: where does this fit in CV risk management?
Speakers:
Professor J. McMurray, Doctor D. Fitchett, Professor J. Deanfield, Professor S. Inzucchi, Doctor D. Fitchett...
About the event
ESC 365 is supported by
